HC Wainwright Cuts Earnings Estimates for Orchestra BioMed

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Equities researchers at HC Wainwright cut their FY2025 earnings estimates for shares of Orchestra BioMed in a research report issued on Thursday, November 13th. HC Wainwright analyst Y. Chen now expects that the company will earn ($1.73) per share for the year, down from their prior estimate of ($1.67). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q4 2025 earnings at ($0.38) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.63) EPS.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. The company had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $0.74 million.

Several other brokerages also recently issued reports on OBIO. BTIG Research reaffirmed a “neutral” rating on shares of Orchestra BioMed in a research report on Wednesday, August 20th. Barclays lowered their price target on shares of Orchestra BioMed from $12.00 to $11.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.25.

Orchestra BioMed Price Performance

OBIO stock opened at $4.23 on Monday. The stock has a 50-day simple moving average of $3.27 and a 200-day simple moving average of $3.02. The firm has a market cap of $238.85 million, a P/E ratio of -2.32 and a beta of 0.65. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $6.30.

Institutional Investors Weigh In On Orchestra BioMed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after purchasing an additional 7,036 shares during the last quarter. IFP Advisors Inc raised its stake in Orchestra BioMed by 106.4% during the first quarter. IFP Advisors Inc now owns 161,921 shares of the company’s stock valued at $693,000 after buying an additional 83,481 shares in the last quarter. Deutsche Bank AG raised its stake in Orchestra BioMed by 67.3% during the first quarter. Deutsche Bank AG now owns 20,219 shares of the company’s stock valued at $87,000 after buying an additional 8,134 shares in the last quarter. Nuveen LLC bought a new position in Orchestra BioMed during the 1st quarter worth approximately $179,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Orchestra BioMed in the 2nd quarter worth approximately $122,000. Institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.